A new, powerful Citizen Portal experience is ready. Switch now

Committee weighs PrEP/PEP coverage and pharmacist-prescribing language in H.611; DVHA flags fiscal and enrollment issues

April 14, 2026 | Health & Welfare, SENATE, Committees, Legislative , Vermont


This article was created by AI summarizing key points discussed. AI makes mistakes, so for full details and context, please refer to the video of the full meeting. Please report any errors so we can fix them. Report an error »

Committee weighs PrEP/PEP coverage and pharmacist-prescribing language in H.611; DVHA flags fiscal and enrollment issues
During markup of H.611 the committee considered an amendment seeking coverage of pre-exposure prophylaxis (PrEP) without cost sharing and authority for pharmacists to prescribe and dispense HIV prevention drugs.

Witnesses and staff noted that federally required coverage already applies to PrEP because of a U.S. Preventive Services Task Force A recommendation, but that PEP (post-exposure prophylaxis) is not currently covered without cost sharing. A hospital-affiliated witness and other advocates urged coverage and easier pharmacy access. One witness said PEP must be taken within 72 hours of exposure to be effective.

Alex McCracken of the Department of Vermont Health Access warned that expanding coverage or adding a mandate would have a fiscal impact for Medicaid and likely require an appropriation. McCracken also flagged a technical drafting issue: Medicaid generally requires that providers be enrolled in the program to be reimbursed, so language that prohibits refusal of reimbursement based on a provider's category could conflict with federal Medicaid enrollment rules. The department recommended amending the draft to address enrollment and reimbursement mechanics and requested cost estimates.

Staff and other committee speakers relayed concerns raised by insurers (Blue Cross) about administrative difficulties in distinguishing prescriptions written for prevention from prescriptions written for treatment, which complicates cost-sharing waivers tied to diagnosis.

Committee members asked staff to coordinate with the Office of Professional Regulation (OPR) and other stakeholders; OPR staff indicated the OPR bill may be a vehicle for some pharmacist-prescribing language and agreed to share draft provisions.

No formal vote was recorded; committee staff said cost estimates and edited draft language would be prepared for future consideration.

Don't Miss a Word: See the Full Meeting!

Go beyond summaries. Unlock every video, transcript, and key insight with a Founder Membership.

Get instant access to full meeting videos
Search and clip any phrase from complete transcripts
Receive AI-powered summaries & custom alerts
Enjoy lifetime, unrestricted access to government data
Access Full Meeting

30-day money-back guarantee